Leerink Partnrs Weighs in on TENX Q1 Earnings

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Tenax Therapeutics in a research report issued on Wednesday, March 26th. Leerink Partnrs analyst D. Risinger expects that the specialty pharmaceutical company will post earnings of ($1.06) per share for the quarter. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Leerink Partnrs also issued estimates for Tenax Therapeutics’ Q2 2025 earnings at ($1.12) EPS, Q3 2025 earnings at ($3.52) EPS, Q4 2025 earnings at ($4.73) EPS, FY2025 earnings at ($10.46) EPS, FY2026 earnings at ($5.76) EPS, FY2027 earnings at ($4.86) EPS, FY2028 earnings at ($3.08) EPS and FY2029 earnings at ($1.03) EPS.

A number of other equities analysts have also commented on the stock. William Blair reiterated an “outperform” rating on shares of Tenax Therapeutics in a report on Monday, March 10th. Leerink Partners set a $20.00 target price on shares of Tenax Therapeutics in a research report on Monday, March 10th. Finally, StockNews.com initiated coverage on shares of Tenax Therapeutics in a report on Saturday. They issued a “sell” rating for the company. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $18.00.

Tenax Therapeutics Price Performance

NASDAQ:TENX opened at $6.36 on Monday. Tenax Therapeutics has a one year low of $2.77 and a one year high of $7.89. The company has a market cap of $25.25 million, a PE ratio of -1.20 and a beta of 2.20. The firm’s 50 day simple moving average is $6.44 and its 200 day simple moving average is $5.48.

Tenax Therapeutics (NASDAQ:TENX) last announced its quarterly earnings results on Tuesday, March 25th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.34.

Institutional Trading of Tenax Therapeutics

Institutional investors have recently modified their holdings of the business. Sphera Funds Management LTD. purchased a new position in shares of Tenax Therapeutics in the third quarter valued at $101,000. Geode Capital Management LLC boosted its stake in Tenax Therapeutics by 32.4% in the 4th quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock worth $151,000 after purchasing an additional 5,964 shares during the period. Janus Henderson Group PLC purchased a new position in Tenax Therapeutics during the 4th quarter valued at about $1,026,000. Millennium Management LLC bought a new stake in shares of Tenax Therapeutics during the fourth quarter valued at about $166,000. Finally, Two Sigma Investments LP purchased a new stake in shares of Tenax Therapeutics in the fourth quarter worth about $84,000. 1.67% of the stock is currently owned by hedge funds and other institutional investors.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.